Secondary Logo

Journal Logo

PROTOCOL ALERT

doi: 10.1097/01.COT.0000289209.70021.b1
PROTOCOL ALERT
Free

The following is a partial list of new clinical trials recently added to the NCI's Physician Data Query (PDQ) database, accessible online at www.cancer.gov.

Back to Top | Article Outline

Bladder Cancer

E-3897: Phase II Study of Intravesical AD 32 in Patients with Recurrent or Refractory Papillary Transitional Cell Carcinoma and/or Carcinoma In Situ of the Bladder

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI cooperative group program, NJ-approved

LEAD ORGANIZATIONS/CHAIRPERSONS

Jeffrey Mark Ignatoff, Chairman, Ph: 847-475-8600

Evanston Northwestern Healthcare

1000 Central Street

Suite 720

Evanston, IL 60201

Richard E. Greenberg, Protocol Co-chairman, Ph: 215-728-5341

Fox Chase Cancer Center

7701 Burholme Avenue

Philadelphia, PA 19111

LEAD ORGANIZATION: Eastern Cooperative Oncology Group

EORTC-30004: Phase III Randomized Study of Chemoresection with Mitomycin versus Transurethral Resection Followed by Mitomycin in Patients with Low-Risk Superficial Transitional Cell Carcinoma of the Bladder

AGE RANGE: 80 and under

SPONSORSHIP: Non-US clinical trials group

LEAD ORGANIZATIONS/CHAIRPERSONS:

Willem Oosterlinck, Chairman, Ph: 9-2402276

Universitair Ziekenhuis Gent

De Pintelaan 185

B-9000 Ghent (Gent), Belgium

LEAD ORGANIZATION: EORTC Genito-Urinary Tract Cancer Group

Back to Top | Article Outline

Brain Cancers

PBTC-007: Phase I/II Study of ZD 1839 and Brain Irradiation in Children with Newly Diagnosed Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas

AGE RANGE: 3 to 21

SPONSORSHIP: NCI-sponsored, NCI CTEP-approved, NCI grant supported

LEAD ORGANIZATIONS/CHAIRPERSONS:

J. Russell Geyer, Chairman, Ph: 206-526-2106

Children's Hospital and Regional Medical Center, Seattle

Department of Pediatric Hematology/Oncology CH-29

4800 Sand Point Way NE

Seattle, WA 98105

Peter C. Phillips, Protocol Co-chairman, Ph: 215-590-2107

Children's Hospital of Philadelphia

Neuro-Oncology Laboratory

515 Abramson Bldg.

34th Street and Civic Center Blvd.

324 South 34th Street

Philadelphia, PA 19104

LEAD ORGANIZATION: Pediatric Brain Tumor Consortium

Back to Top | Article Outline

Breast Cancer

ACRIN-6657: Diagnostic Study of Contrast-Enhanced Breast Magnetic Resonance Imaging for Women with Stage III Breast Cancer Who Are Receiving Neoadjuvant Chemotherapy

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI cooperative group program

LEAD ORGANIZATIONS/CHAIRPERSONS:

Bruce J. Hillman, Chairman, Ph: 434-982-0211

University of Virginia

Health Science Center

P.O. Box 800170

Charlottesville, VA 22908

Edward Sickles, Protocol Co-chairman, Ph: 415-885-7417

UCSF Cancer Center and Cancer Research Institute

University of California-San Francisco

2340 Sutter Street, Box 0128 UCSF

San Francisco, CA 94143-0128

LEAD ORGANIZATION: American College of Radiology Imaging Network

Back to Top | Article Outline

Colorectal Cancer

E-3200, CTSU: Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium with or without Bevacizumab versus Bevacizumab Only in Patients with Previously Treated Advanced or Metastatic Colorectal Adenocarcinoma

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI cooperative group program

LEAD ORGANIZATIONS/CHAIRPERSONS:

Bruce J. Giantonio, Chairman, Ph: 215-662-8756

University of Pennsylvania Health Systems

Medical Arts Building-Suite 103

51 North 39th Street

Philadelphia, PA 19104-9104

Neal Jay Meropol, Protocol Co-chairman, Ph: 215-728-2450

Fox Chase Cancer Center

Medical Oncology

7701 Burholme Avenue

Philadelphia, PA 19111

Peter J. O'Dwyer, Protocol Co-chairman, Ph: 215-662-8636

University of Pennsylvania Cancer Center

51 North 39th Street -M.A.B. 103

Philadelphia, PA 19104-4283

LEAD ORGANIZATION: Eastern Cooperative Oncology Group

NCI-02-C-0194: Phase II Randomized Chemoprevention Study of Celecoxib in Patients with Premalignant Rectal Polyps or Prior Sporadic Colorectal Neoplasia

AGE RANGE: 18 and over

TYPE: Prevention

SPONSORSHIP: NCI-sponsored

LEAD ORGANIZATIONS/CHAIRPERSONS

Ernest Hawk, Chairman, Ph: 301-594-2684

Division of Cancer Prevention

National Cancer Institute

National Institutes of Health

GI and Other Cancers Research Group NCI/DCP

6130 Executive Blvd. Room 2141

Rockville, MD 20852

LEAD ORGANIZATION: Center for Cancer Research

Back to Top | Article Outline

Leukemias

MSKCC-00116, NCI-1715: Phase II Pilot Study of FR901228 in Patients with Myelodysplastic Syndromes, Acute Myeloid Leukemia, or Intermediate-Grade Diffuse or Follicular Non-Hodgkin's Lymphoma

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI CTEP-approved

LEAD ORGANIZATIONS/CHAIRPERSONS:

David R. Spriggs, Chairman, Ph: 212-639-2203

Chief, Developmental Chemotherapy

Memorial Sloan-Kettering Cancer Center

Department of Medical Oncology

1275 York Avenue

New York, NY 10021

LEAD ORGANIZATION: Memorial Sloan-Kettering Cancer Center

COG-ADVL0114: Phase I Study of Decitabine in Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

AGE RANGE: Under 22

SPONSORSHIP: NCI-sponsored, NCI cooperative group program

LEAD ORGANIZATIONS/CHAIRPERSONS:

Gregory H. Reaman, Chairman, Ph: 202-884-2147

Chairman, Department of Hematology/Oncology

Children's National Medical Center

111 Michigan Avenue NW

Washington, DC 20010-2970

LEAD ORGANIZATION: Children's Oncology Group

Back to Top | Article Outline

Lung Cancer

CLB-30103: Phase II Randomized Study of Carboplatin and Etoposide with or without Oblimersen in Patients with Extensive Stage Small Cell Lung Cancer

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI cooperative group program

LEAD ORGANIZATIONS/CHAIRPERSONS:

Richard L. Schilsky, Chairman, Ph: 773-834-3914

University of Chicago

Biological Sciences Division

5841 South Maryland Avenue, MC 1000

Chicago, IL 60637

LEAD ORGANIZATION: Cancer and Leukemia Group B

UCLA-0201030, NCI-G02-2100, NWBI-DC1-NSCLC: Phase I Study of Mature Autologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells (DCVax-Lung) in Patients with Non-Small Cell Lung Cancer

AGE RANGE: 18 and over

SPONSORSHIP: Pharmaceutical, NCI-sponsored, NCI-sponsored trial in cancer center

LEAD ORGANIZATIONS/CHAIRPERSONS:

Barbara J. Gitlitz, Chairman. Ph: 310-825-5788

UCLA

10945 LeConte Avenue

Division of Oncology, 2333 PVUB

Los Angeles, CA 90024

LEAD ORGANIZATION: Jonsson Comprehensive Cancer Center, UCLA

FCCC-02014, NCI-G02-2097: Phase II Study of Induction with Paclitaxel, Carboplatin, and Radiotherapy Followed by Surgical Resection and Adjuvant Paclitaxel and Carboplatin in Patients with Locally Advanced Non-Small Cell Lung Cancer

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI-sponsored trial in cancer center

LEAD ORGANIZATIONS/CHAIRPERSONS:

Corey Jay Langer, Chairman, Ph: 215-728-2985

Fox Chase Cancer Center

Department of Medical Oncology

7701 Burholme Avenue

Philadelphia, PA 19111

LEAD ORGANIZATION: Fox Chase Cancer Center

UCCRC-11432B, NCI-5411: Phase I Study of Erlotinib and Radiotherapy Plus Either Cisplatin, Etoposide, and Docetaxel or Carboplatin and Paclitaxel in Patients with Inoperable Stage III Non-Small Cell Lung Cancer

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI CTEP-approved, NCI grant supported

LEAD ORGANIZATIONS/CHAIRPERSONS:

Ann M. Mauer, Chairman, Ph: 773-702-4138

University of Chicago Cancer Research Center

Mail Code 9015

5758 South Maryland Avenue

Chicago, IL 60637-1470

LEAD ORGANIZATION: University of Chicago Cancer Research Center

Back to Top | Article Outline

Lymphomas

MSKCC-00116, NCI-1715: Phase II Pilot Study of FR901228 in Patients with Myelodysplastic Syndromes, Acute Myeloid Leukemia, or Intermediate-Grade Diffuse or Follicular Non-Hodgkin's Lymphoma

AGE RANGE: 18 and over

SPONSORSHIP: NCI-sponsored, NCI CTEP-approved

LEAD ORGANIZATIONS/CHAIRPERSONS:

David R. Spriggs, Chairman, Ph: 212-639-2203

Chief, Developmental Chemotherapy

Memorial Sloan-Kettering Cancer Center

Department of Medical Oncology

1275 York Avenue

New York, NY 10021

LEAD ORGANIZATION: Memorial Sloan-Kettering Cancer Center

UCLA-0201056, NCI-G02-2094, AMGEN-AMG-412-159: Phase II Randomized Study of Epratuzumab in Patients with Diffuse Large B-Cell Non-Hodgkin's Lymphoma

AGE RANGE: 18 and over

SPONSORSHIP: Pharmaceutical, NCI-sponsored, NCI-sponsored trial in cancer center

LEAD ORGANIZATIONS/CHAIRPERSONS:

Christos E. Emmanouilides, Chairman, Ph: 310-206-0716

Jonsson Comprehensive Cancer Center, UCLA

Department of Medicine, Division of HEM/ONC

42-121 CHS

10833 Le Conte Avenue

Los Angeles, CA 90095-1781

LEAD ORGANIZATION: Jonsson Comprehensive Cancer Center

Back to Top | Article Outline

Melanoma

SWOG-S0116: Phase II Study of D1/3-MAGE-3-His Fusion Protein with SB-AS02B Adjuvant in Patients with Stage IV Melanoma

SPONSORSHIP: NCI-sponsored, NCI cooperative group program

LEAD ORGANIZATIONS/CHAIRPERSONS:

Charles A. Coltman, Jr., Chairman, Ph: 210-616-5580

Director

San Antonio Cancer Institute

7979 Wurzbach, Urschel Tower

Suite 500

San Antonio, TX 78229

Vernon K. Sondak, Protocol Co-chairman, Ph: 734-936-7938

University of Michigan

1500 East Medical Center Drive, Box 0932, Suite 3306 CCGC

Ann Arbor, MI 48109

Mary L. (Nora) Disis, Protocol Co-chairman, Ph: 206-616-1823

University of Washington School of Medicine

Division of Oncology

Box 356527

Seattle, WA 98195-6527

LEAD ORGANIZATION: Southwest Oncology Group

Back to Top | Article Outline

Pediatric Cancers

COG-ADVL0114: Phase I Study of Decitabine in Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

AGE RANGE: Under 22

SPONSORSHIP: NCI-sponsored, NCI cooperative group program

LEAD ORGANIZATIONS/CHAIRPERSONS:

Gregory H. Reaman, Chairman, Ph: 202-884-2147

Chairman, Department of Hematology/Oncology

Children's National Medical Center

111 Michigan Avenue NW

Washington, DC 20010-2970

LEAD ORGANIZATION: Children's Oncology Group

PBTC-007: Phase I/II Study of ZD 1839 and Brain Irradiation in Children with Newly Diagnosed Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas

AGE RANGE: 3 to 21

SPONSORSHIP: NCI-sponsored, NCI CTEP-approved, NCI grant supported

LEAD ORGANIZATIONS/CHAIRPERSONS:

J. Russell Geyer, Chairman, Ph: 206-526-2106

Children's Hospital and Regional Medical Center, Seattle

Department of Pediatric Hematology/Oncology CH-29

4800 Sand Point Way NE

Seattle, WA 98105

Peter C. Phillips, Protocol Co-chairman, Ph: 215-590-2107

Children's Hospital of Philadelphia

Neuro-Oncology Laboratory

515 Abramson Bldg.

34th Street and Civic Center Blvd.

324 South 34th Street

Philadelphia, PA 19104

LEAD ORGANIZATION Pediatric Brain Tumor Consortium

Back to Top | Article Outline

Prostate Cancer

NCCTG-N01C8, NCI-P02-0229: Phase III Randomized Study of Calcium and Cholecalciferol with or without Conjugated Estrogens and with or without Risedronate for the Prevention of Osteoporosis in Patients with Prostate Cancer Receiving Androgen Ablation Therapy

AGE RANGE: 18 and over

TYPE: Supportive care

SPONSORSHIP: NCI-sponsored, NCI cooperative group program, NCI DCP cancer control study

LEAD ORGANIZATIONS/CHAIRPERSONS:

Michael J. O'Connell, Chair, Ph: 507-284-2511

Mayo Clinic Cancer Center

200 First Street SW

Rochester, MN 55905

Ann E. Kearns, Protocol Co-chairman, Ph: 507-284-3903

Mayo Clinic

200 First Street Southwest

Rochester, MN 55905

Stacy D. Jacobson, Protocol Co-chairman, Ph: 507-284-1623

Mayo Clinic

200 First Street Southwest

Rochester, MN 55905

LEAD ORGANIZATION: North Central Cancer Treatment Group

© 2002 Lippincott Williams & Wilkins, Inc.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!